HOME >> BIOLOGY >> NEWS
UCF brain cell research spawns hope for longer life

stents and other devices that are prone to inflammatory reactions.

Initial tests show that the nanoparticle anti-oxidants regenerate once they penetrate the cell -- meaning one dose could conceivably continue its therapeutic effects indefinitely.

Rzigalinski introduced the collaboration to her colleagues at the NATURE biotechnology symposium in Miami earlier this year. She has also submitted an abstract on the project to the National and International Neurotrauma Symposium, and Society for Neuroscience.

Nanotechnology is considered the new frontier of science, and it could revolutionize modern medicine in the future. The potential for creating new materials at a size capable of being absorbed by human cells calls for a new type of scientist -- one who can collaborate across seemingly unrelated disciplines. Combining the fields of biomolecular science with engineering offers a significant step in that direction.

Pappachan Kolattukudy, director of UCF's Biomolecular Science Center and a consultant on the project, said the collaboration is part of a strategy that UCF is going to be using increasingly in building its presence in the biomolecular sciences.

"We are concentrating on building interfaces between areas in which we have strengths," Kolattukudy said.

Vimal Desai, director of AMPAC, said that nanomaterials are currently considered highly strategic for important applications ranging from homeland security to just plain good health.

"It is so good to be able to build bridges for an interdisciplinary effort through competent and dynamic researchers at UCF," Desai said.


'"/>

Contact: Barb Abney
bcompton@mail.ucf.edu
407-823-5139
University of Central Florida
13-Aug-2003


Page: 1 2 3

Related biology news :

1. Trial shows which brain cancer patients benefit from temozolomide
2. Targeted therapy knocks out pediatric brain cancer in mice
3. New way to protect brain from stroke damage
4. Chemical signals health of brain cells Symposium
5. DHA-rich diet protects brain from Alzheimers damage, UCLA study shows
6. Decreasing toxins in brains of Alzheimers patients keep cognitive deficits at bay
7. Genetic clues found for common congenital brain disorder
8. Marijuana ingredient inhibits VEGF pathway required for brain tumor blood vessels
9. Molecular therapeutics advance fight against brain cancer
10. Depression traced to overactive brain circuit
11. Clusters of alterations on PIK3CA gene found in brain cancers

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: UCF brain cell research spawns hope for longer life

(Date:7/23/2015)... (NASDAQ: AWRE ), a leading supplier of biometrics software ... ended June 30, 2015.  Revenue for the ... 33% compared to $6.8 million in the same quarter last ... $0.3 million, or $0.01 per diluted share, which compared to ... period a year ago.  Lower revenue and ...
(Date:7/21/2015)... Passwords have proven futile for securing ... U.S. Office of Personnel Management breach. Biometric authentication ... but developers and end-users are concerned about how ... Biometrics-as-a-Service provider HYPR Corp. announced today the general ... party integration. A video overview ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the fourth quarter ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
(Date:7/30/2015)... ... July 31, 2015 , ... Ralco is honored to announce ... Lyon County Fair to be held August 5-9 in Marshall. The Ralco Enrichment Center ... come from and how agriculture impacts their daily lives. This unique exhibit also features ...
(Date:7/30/2015)... Washington , July 30, 2015 ... Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial ... Discovery & Development, Preclinical, Clinical Trial), by End Users ... Biosimulation Market is expected to reach USD 2,107.99 million ... a CAGR of 15.29%. Browse more ...
(Date:7/30/2015)... 2015 Ascendis Pharma A/S (Nasdaq: ... innovative TransCon technology to address significant unmet medical ... six-month Phase 2 study to evaluate the safety ... 53 treatment-naïve, pre-pubertal children with growth hormone deficiency, ... with the top-line results from our Phase 2 ...
(Date:7/29/2015)... 2015 Sanofi, a global ... second quarter of 2015. CEO Olivier Brandicourt ... performance in different businesses. Watch video ... Topics covered in the interview ... - Performance drivers - Diabetes ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
Cached News: